Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)

被引：0
|
作者：
Iwamoto, M. [1 ]
Matsutani, A. [1 ]
Ikari, A. [1 ]
Tominaga, T. [1 ]
Maezawa, S. [1 ]
Oku, H. [1 ]
Kimura, K. [1 ]
机构：
[1] Osaka Med Coll, Breast Surg, Osaka, Japan
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P086
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [41] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
    Waks, Adrienne G.
    Desai, Neelam V.
    Li, Tianyu
    Poorvu, Philip D.
    Partridge, Ann H.
    Sinclair, Natalie
    Spring, Laura M.
    Faggen, Meredith
    Constantine, Michael
    Metzger, Otto
    Alberti, Jillian
    Deane, Julia
    Rosenberg, Shoshana M.
    Frank, Elizabeth
    Tolaney, Sara M.
    Krop, Ian E.
    Tung, Nadine M.
    Tayob, Nabihah
    King, Tari A.
    Mittendorf, Elizabeth A.
    Winer, Eric P.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [42] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
    Adrienne G. Waks
    Neelam V. Desai
    Tianyu Li
    Philip D. Poorvu
    Ann H. Partridge
    Natalie Sinclair
    Laura M. Spring
    Meredith Faggen
    Michael Constantine
    Otto Metzger
    Jillian Alberti
    Julia Deane
    Shoshana M. Rosenberg
    Elizabeth Frank
    Sara M. Tolaney
    Ian E. Krop
    Nadine M. Tung
    Nabihah Tayob
    Tari A. King
    Elizabeth A. Mittendorf
    Eric P. Winer
    npj Breast Cancer, 8
  • [43] BIOMARKER (BM) ANALYSES OF A PHASE II STUDY OF NEOADJUVANT PERTUZUMAB AND TRASTUZUMAB WITH AND WITHOUT ANTHRACYCLINE (ATC)-CONTAINING CHEMOTHERAPY FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (BC) (TRYPHAENA)
    Schneeweiss, A.
    Chia, S.
    Hegg, R.
    Tausch, C.
    Deb, R.
    Ratnayake, J.
    Kiermaier, A.
    McNally, V.
    Ross, G.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 83 - 83
  • [44] Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
    Conlin, Alison K.
    Seidman, Andrew D.
    Bach, Ariadne
    Lake, Diana
    Dickler, Maura
    D'Andrea, Gabriella
    Traina, Tiffany
    Danso, Michael
    Brufsky, Adam M.
    Saleh, Mansoor
    Clawson, Alicia
    Hudis, Clifford A.
    CLINICAL BREAST CANCER, 2010, 10 (04) : 281 - 287
  • [45] Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
    Schneeweiss, A.
    Chia, S.
    Hickish, T.
    Harvey, V.
    Eniu, A.
    Hegg, R.
    Tausch, C.
    Seo, J. H.
    Tsai, Y. -F.
    Ratnayake, J.
    McNally, V.
    Ross, G.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2278 - 2284
  • [46] Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)
    Schneeweiss, A.
    Chia, S.
    Hickish, T.
    Harvey, V.
    Eniu, A.
    Waldron-Lynch, M.
    Eng-Wong, J.
    Kirk, S.
    Cortes, J.
    CANCER RESEARCH, 2017, 77
  • [47] Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+patients (pts)
    Raefsky, E.
    Inhorn, R.
    Lange, M.
    Peacock, N.
    Shastry, M.
    Vazquez, E.
    Priego, V.
    Franco, L.
    Hainsworth, J. D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute
    Yardley, Denise A.
    Zubkus, John D.
    Eakle, Janice F.
    Bechhold, Rebecca G.
    Finney, Lindsey
    Daniel, Davey
    Daniel, Brooke
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2015, 15 (04) : 251 - 258
  • [49] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749
  • [50] Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive/HER2-positive breast cancer - The TOUCH trial
    Biganzoli, Laura
    Brain, Etienne
    Malorni, Luca
    Gombos, Andrea
    Hasler-Strub, Ursula
    Zamagni, Claudio
    Chakiba, Camille
    Roschitzki-Voser, Heidi
    Regan, Meredith M.
    CANCER RESEARCH, 2021, 81 (04)
12345